Tirzepatide injections are weight loss injections administered weekly by an subcutaneous injection( It is sold under the brand name of Mounjaro). Tirzepatide is similar to the medication of semaglutide in that it mimics the GLP-1 hormone but it has targets the GIP. In trials, tirzepatide has shown superior weight loss over placebo and also semaglutide. IVFusionMD delivers an all-in-one consultation, weight tracking, and tirzepatide injections to you. Our doctors will access if you are a candidate for this weight loss treatment.
Tirzepatide is an injectable medication that is dual targeting. It works as a glucagon-like peptide-1 ( GLP-1 ) and also a glucose-dependent insulinotropic polypeptide ( GIP ). It was approved by the FDA in 2022 for treatment of diabetes type 2 for control of blood glucose under the name Mounjaro. Semaglutide which is another injectable medication for diabetes type 2 (branded under Ozempic) and weight loss (branded under Wegovy) Semaglutide was FDA approved in 2017 by the FDA for diabetes and then approved for weight loss in 2021. Both Ozempic and Wegovy are semaglutide injectable medications. Semaglutide contrasts tirzepatide in that it only works as a glucagon-like peptide-1.
The glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide are both incretin hormones released by your body. They are released a few minutes after a meal and targets an increase in insulin and also lowers glucagon secretion. This lowers the post meal blood sugar spike. They both work on signaling the brain to regulate appetite and food consumption.
The tirzepatide injections are done under the skin or subcutaneously on your thigh, stomach area, or upper arm. The injections are given once a week and the dosages are tapered up over a course of several weeks customized to your weight loss, side effects. The maximum dosage is 15 mg weekly. A slow taper will reduce the chances of gastrointestinal side effects that may arise.
Most common side effects of the injection include:
A slow taper and customizing dosages is helpful with decreasing the chances of getting these side effects.
In the five FDA clinical trials for Mounjaro, patients on Mounjaro lost 15 more pounds than placebo. Patients also lost about 12 pounds more than one semaglutide. In the recent SURMOUNT-2 randomized double blind clinical trials, Mounjaro has shown superior weight loss at an average of 15.7% at 72 weeks.
At any IVfusionMD location, you can get a consultation with our providers to discuss if tirzepatide injections are right for you and your weight loss journey.
If you’d like to make an appointment for weight loss management, please book your appointment online or call IVFusionMD. We look forward to helping you with optimizing your wellness and health.